Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Lupin Ltd with Sun Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

LUPIN vs SUN PHARMA - Comparison Results

LUPIN    Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More


Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More


Current Valuations

P/E (TTM) x 41.4 24.9 166.1% View Chart
P/BV x 2.5 2.6 96.6% View Chart
Dividend Yield % 0.7 0.5 136.2%  


5-Yr Chart
Click to enlarge
High Rs1,465701 209.1%   
Low Rs727433 167.8%   
Sales per share (Unadj.) Rs349.6110.4 316.6%  
Earnings per share (Unadj.) Rs5.611.0 50.6%  
Cash flow per share (Unadj.) Rs29.617.2 171.7%  
Dividends per share (Unadj.) Rs5.002.00 250.0%  
Dividend yield (eoy) %0.50.4 129.3%  
Book value per share (Unadj.) Rs300.3158.8 189.1%  
Shares outstanding (eoy) m452.082,399.26 18.8%   
Bonus/Rights/Conversions ESOPS--  
Price / Sales ratio x3.15.1 61.1%   
Avg P/E ratio x197.251.6 381.9%  
P/CF ratio (eoy) x37.132.9 112.6%  
Price / Book Value ratio x3.63.6 102.2%  
Dividend payout %90.018.2 493.8%   
Avg Mkt Cap Rs m495,5021,360,021 36.4%   
No. of employees `00017.017.8 95.8%   
Total wages/salary Rs m28,64753,671 53.4%   
Avg. sales/employee Rs Th9,273.614,890.9 62.3%   
Avg. wages/employee Rs Th1,681.03,017.1 55.7%   
Avg. net profit/employee Rs Th147.41,480.6 10.0%   
Net Sales Rs m158,042264,895 59.7%  
Other income Rs m1,5048,388 17.9%   
Total revenues Rs m159,545273,282 58.4%   
Gross profit Rs m31,47556,081 56.1%  
Depreciation Rs m10,85914,998 72.4%   
Interest Rs m2,0445,176 39.5%   
Profit before tax Rs m20,07644,295 45.3%   
Minority Interest Rs m-710-   
Prior Period Items Rs m350-   
Extraordinary Inc (Exp) Rs m-14,644-9,505 154.1%   
Tax Rs m2,8858,452 34.1%   
Profit after tax Rs m2,51326,338 9.5%  
Gross profit margin %19.921.2 94.1%  
Effective tax rate %14.419.1 75.3%   
Net profit margin %1.69.9 16.0%  
Current assets Rs m122,095316,359 38.6%   
Current liabilities Rs m50,956198,643 25.7%   
Net working cap to sales %45.044.4 101.3%  
Current ratio x2.41.6 150.5%  
Inventory Days Days8595 89.2%  
Debtors Days Days120108 111.4%  
Net fixed assets Rs m129,876213,178 60.9%   
Share capital Rs m9042,399 37.7%   
"Free" reserves Rs m134,866378,606 35.6%   
Net worth Rs m135,771381,006 35.6%   
Long term debt Rs m64,24517,721 362.5%   
Total assets Rs m263,054643,028 40.9%  
Interest coverage x10.89.6 113.2%   
Debt to equity ratio x0.50 1,017.4%  
Sales to assets ratio x0.60.4 145.8%   
Return on assets %1.74.9 35.3%  
Return on equity %1.96.9 26.8%  
Return on capital %3.710.0 37.1%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m53,14140,816 130.2%   
Fx outflow Rs m19,33530,143 64.1%   
Net fx Rs m33,80710,673 316.7%   
From Operations Rs m17,51239,072 44.8%  
From Investments Rs m-14,073-33,708 41.7%  
From Financial Activity Rs m-14,921-15,393 96.9%  
Net Cashflow Rs m-11,482-7,359 156.0%  

Share Holding

Indian Promoters % 46.6 63.7 73.2%  
Foreign collaborators % 0.2 0.0 -  
Indian inst/Mut Fund % 11.3 5.1 220.3%  
FIIs % 31.9 23.0 138.7%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.1 8.3 121.7%  
Shareholders   98,259 133,026 73.9%  
Pledged promoter(s) holding % 0.0 0.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster


Compare LUPIN With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  

Today's Market

Modi's Victory Creates Sensex History; Ache Din Ahead?(Podcast)

Throughout the week, one slogan that took over the market and country as a whole was, Ab ki baar phir Modi Sarkar.

Related Views on News

LUPIN Announces Quarterly Results (4QFY19); Net Profit Down 1.5% (Quarterly Result Update)

May 17, 2019 | Updated on May 17, 2019

For the quarter ended March 2019, LUPIN has posted a net profit of Rs 3 bn (down 1.5% YoY). Sales on the other hand came in at Rs 44 bn (up 77.8% YoY). Read on for a complete analysis of LUPIN's quarterly results.

LUPIN LTD Announces Quarterly Results (3QFY19); Net Profit Down 149.7% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, LUPIN LTD has posted a net profit of Rs 2 bn (down 149.7% YoY). Sales on the other hand came in at Rs 45 bn (up 78.0% YoY). Read on for a complete analysis of LUPIN LTD's quarterly results.

SUN PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 265.5% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, SUN PHARMA has posted a net profit of Rs 15 bn (up 265.5% YoY). Sales on the other hand came in at Rs 77 bn (up 16.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

SUN PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 20, 2018 | Updated on Dec 20, 2018

Here's an analysis of the annual report of SUN PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUN PHARMA. Also includes updates on the valuation of SUN PHARMA.

SUN PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 110.7% (Quarterly Result Update)

Nov 14, 2018 | Updated on Nov 14, 2018

For the quarter ended September 2018, SUN PHARMA has posted a net profit of Rs 1 bn (down 110.7% YoY). Sales on the other hand came in at Rs 69 bn (up 4.3% YoY). Read on for a complete analysis of SUN PHARMA's quarterly results.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.

The Bitter Pill that Will Lay the Foundation for Sensex 100,000(The 5 Minute Wrapup)

May 14, 2019

These companies will help the Sensex more than double from current levels.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


May 24, 2019 (Close)